Brought to you by 
APT gets rights to Novartis' inhalable cyclosporine
15 May 2012
Executive Summary
Novartis has granted APT Pharmaceuticals (repurposes existing drugs) exclusive worldwide rights to develop and market an inhalable form of cyclosporine to prevent and treat lung transplant rejection.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
APT gets rights to Novartis' inhalable cyclosporine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice